PEP-07 is under clinical development by Sentinel Oncology and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PEP-07’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PEP-07 overview
PEP-07 (CASC-578) is under development for the treatment of metastatic solid tumor, relapsed and refractory acute myeloid leukemia, mantle cell lymphoma, and non-small cell lung cancer. The drug candidate acts by targeting checkpoint kinase 1 (Chk1).
Sentinel Oncology overview
Sentinel Oncology (Sentinel) is a drug discovery company that develops and commercializes new therapeutics to treat cancer patients. The company’s pipeline products include SOL578 which treats hematological and solid tumors; SOL784 for fragile X syndrome; SOL686 treats solid tumors. Sentinel also develops treatment for solid tumors such as targeted synergy in which a drug can be delivered and activated in the hypoxic micro-environment that is found in solid tumors. The company collaborates with biotechnology and pharmaceutical sectors. Sentinel is headquartered in Cambridge, the UK.
For a complete picture of PEP-07’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
